Nordic Nanovector’s Capital Increase


Shearman & Sterling advised DNB Markets, Jefferies International Limited, and Kempen & Co. in connection with Nordic Nanovector’s capital increase and issuance of ordinary shares.

Nordic Nanovector intends to use the proceeds of the offering for manufacturing development activities for its lead clinical-stage candidate Betalutin®, for a scale-up of its clinical and commercial activities in preparation for a commercial launch of Betalutin®, as well as for general corporate purposes.

Nordic Nanovector is a Norwegian biopharmaceutical company committed to developing and delivering innovative therapies to patients to address major unmet medical needs and advance cancer care, and aspires to become a leader in the development of targeted therapies for hematological cancers.

Shearman & Sterling advised DNB Markets, Jefferies International Limited, and Kempen & Co. with a team including David Dixter (Picture), Saif Alaqili, David St-Onge, Kristen Garry and Daniel Kachmar

Involved fees earner: Saif Alaqili – Shearman & Sterling; David Dixter – Shearman & Sterling; Kristen Garry – Shearman & Sterling; Daniel Kachmar – Shearman & Sterling; David St-Onge – Shearman & Sterling;

Law Firms: Shearman & Sterling;

Clients: DNB Markets; Jefferies; Kempen & Co;